Score Of Foreign Drug Makers Face Lower China Price Caps As Of May 1
This article was originally published in PharmAsia News
A score of foreign drug makers face a reduction in the prices they charge for digestive-related drugs in China as a result of a scheduled May 1 lowering of price caps by an average 17%.
You may also be interested in...
Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.
From enforced detention to hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.